Radiopharmaceuticals for diagnosing Alzheimer's disease

Details Radiopharmaceuticals for diagnosing Alzheimer's disease Radiopharmaceuticals for diagnosing Alzheimer's disease

2001-11-06

2004-01-13

Shah, Mukund J. (Department: 1624)

Drug, bio-affecting and body treating compositions

In vivo diagnosis or in vivo testing

C544S391000

Reexamination Certificate

active

06676926

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to novel radiopharmaceuticals useful for the diagnosis of Alzheimer's disease.
BRIEF DESCRIPTION OF THE BACKGROUND ART
Alzheimer's disease is a severe neurodegenerative disorder, and currently about 4 million Americans suffer from this disease. As the aging population continues to grow, this number could reach 14 million by the middle of next century unless a cure or prevention is found. At present, there is no sensitive and specific premortem test for early diagnosis of this disease. Alzheimer's disease is currently diagnosed based on the clinical observation of cognitive decline, coupled with the systematic elimination of other possible causes of those symptoms. The confirmation of the clinical diagnosis of “probable Alzheimer's disease” can only be made by examination of the postmortem brain. The Alzheimer's disease brain is characterized by the appearance of two distinct abnormal proteinaceous deposits in regions of the brain responsible for learning and memory (e.g., cerebral cortex and hippocampus). These deposits are extracellular amyloid plaques, which are characteristic of Alzheimer's disease, and intracellular neurofibillary tangles (NFTs), which can be found in other neurodegenerative disorders as well. Amyloid peptides are typically either 40 or 42 amino acids in length (“A
1-40
” or “A
1-42
”, respectively) and are formed from abnormal processing of a larger membrane-associated protein of unknown function, the amyloid precurser protein (“APP”). Oligomeric aggregates of these peptides are thought to be neurotoxic, eventually resulting in synaptic degeneration and neuronal loss. The amount of amyloid deposition roughly correlates with the severity of symptoms at the time of death.
In the past, there have been several attempts for the design of radiopharmaceuticals that could be used as diagnostic agents for a premortem diagnosis of Alzheimer's disease.
Bornebroek et al. showed that the amyloid-associated protein serum amyloid P component (SAP), labeled with
123
I, accumulates at low levels in the cerebral cortex, possibly in vessel walls, of patients with cerebral amyloidosis (Bornebroek, M., et al.,
Nucl. Med. Commun.
(1996), Vol. 17, pp. 929-933).
Saito et al. proposed a vector-mediated delivery of
125
I-labeled A
1-40
through the blood-brain barrier. It is reported that the iodinated A
1-40
binds A amyloid plaque in tissue sections (Saito, Y., et al.,
Proc. Natl. Acad. Sci. USA
1995, Vol. 92, pp.10227-10231).
U.S. Pat. No. 5,231,000 discloses antibodies with specificity to A4 amyloid polypeptide found in the brain of Alzheimer's disease patients. However, a method to deliver these antibodies across the blood-brain barrier has not been described.
Zhen et al. described modifications of the amyloid-binding dye known as “Congo Red™”, and complexes of these modified molecules with technetium and rhenium. The complexes with radioactive ions are purported to be potential imaging agents for Alzheimer's disease (Zhen et al.,
J. Med. Chem.
(1999), Vol. 42, pp. 2805-2815). However, the potential of the complexes to cross the blood-brain barrier is limited.
A group at the University of Pennsylvania in the U.S.A. (Skovronsky, M., et al.,
Proc. Natl. Acad. Sci.
2000, Vol. 97, pp. 7609-7614) has developed a fluorescently labeled derivative of Congo Red that is brain permeable and that non-specifically binds to amyloid materials (that is, peptides in-pleated sheet conformation). This compound would need to be radiolabeled and then run through pre-clinical screens for pharmacokinetics and toxicity before clinical testing.
Klunk et al. reported experiments with a derivative of Congo Red™, Chrysamine G (CG). It is reported that CG binds synthetic-amyloid well in vitro, and crosses the blood-brain barrier in normal mice (Klunk et al.,
Neurobiol. Aging
(1994), Vol. 15, No. 6, pp. 691-698).
Bergström et al. presented a compound labeled with iodine-123 as a potential radioligand for visualization of M
1
and M
2
muscarinic acetylcholine receptors in Alzheimer's disease (Bergström et al.,
Eur. J. Nucl. Med.
(1999), Vol. 26, pp. 1482-1485).
Recently, it has been discovered that certain specific chemokine receptors are upregulated in the brains of patients with Alzheimer's disease (Horuk, R. et al.,
J. Immunol.
(1997), Vol. 158, pp. 2882-2890); Xia et al.,
J. NeuroVirol
(1999), Vol. 5, pp. 32-41). In addition, it has been shown recently that the chemokine receptor CCR1 is upregulated in the brains of patients with advanced Alzheimer's disease and absent in normal-aged brains (Halks-Miller et al,
CCR
1
Immunoreactivity in Alzheimer's Disease Brains
, Society for Neuroscience Meeting Abstract, #787.6, Volume 24, 1998). Antagonists to the CCR1 receptor and their use as anti-inflammatory agents are described in the PCT Published Patent Application, WO 98/56771.
None of the above described proposals have resulted in a clinical development of an imaging agent for the early diagnosis of Alzheimer's disease. Accordingly, there is still a clinical need for a diagnostic agent that could be used for a reliable and early diagnosis of Alzheimer's disease.
SUMMARY OF THE INVENTION
The present invention is directed to radiopharmaceuticals that bind to the CCR1 receptor and are able to pass through the blood-brain barrier, and are therefore useful in diagnosing Alzheimer's disease, preferably at an early stage of the disease.
Accordingly, in one aspect, the invention is directed to compounds of formula (I):
wherein
X
1
and X
2
are each independently halo;
R
1
and R
2
are each independently hydrogen or alkyl; and
R
3
is hydrogen, amino, monoalkylamino, dialkylamino, monoaralkylamino, alkylcarbonylamino, alkenylcarbonylamino, haloalkylcarbonylamino, arylcarbonylamino, alkoxyalkylcarbonylamino, alkoxycarbonylalkylcarbonylamino, glycinamido, monoalkylglycinamido, arylcarbonylglycinamido, aminocarbonylglycinamido, (aminocarbonyl)(alkyl)glycinamido, (alkoxyalkylcarbonyl)glycinamido, ureido, monoalkylureido, monoarylureido, monoaralkylureido, or alaninamido;
and wherein either one of X
1
or X
2
is selected from the group of
123
I,
125
I,
128
I,
131
I,
75
Br,
76
Br,
80
Br and
18
F; or wherein one of the carbon atoms in the compound is
11
C; or a pharmaceutically acceptable salt thereof.
In another aspect, the invention is directed to compounds of formula (II):
wherein
X
1
and X
2
are each independently halo;
R
1
and R
2
are each independently hydrogen or alkyl; and
R
4
is hydrogen; and
R
5
comprises a chelator capable of binding a radioactive metal atom chosen from the group of
99m
Tc,
186
Re and
188
Re;
or as a complex with
99m
Tc,
186
Re and
188
Re;
or a pharmaceutically acceptable salt thereof.
In another aspect, this invention is directed to a method of diagnosing Alzheimer's disease in a human which comprises administering to a human in need of such diagnosis a compound of formula (I) or formula (II), as described above and herein, and measuring the radioactivity arising from the administration of the compound to the human either by using a gamma camera or by positron emission tomography (PET).
In another aspect, the invention is directed to a method of using a compound of the invention for the manufacture of a radiopharmaceutical for the diagnosis of Alzheimer's disease in a human.
In another aspect, the invention is directed to a method of preparing compounds of the invention.
Upon further study of the specification and appended claims, further objects and advantages of this invention will become apparent to those skilled in the art.


REFERENCES:
patent: 5286728 (1994-02-01), Ferrini
patent: 5358712 (1994-10-01), Efange et al.
patent: 5721243 (1998-02-01), Efange et al.
patent: 5919797 (1999-07-01), Goodman et al.
patent: 6207665 (2001-03-01), Bauman et al.
patent: 2 758 328 (1998-07-01), None
patent: WO 92/16239 (1992-10-01), None
patent: WO 96/01656 (1996-01-01), None
patent: WO 98/02151 (1998-01-01), Non

Affiliated with

Also associated with

Rating

Radiopharmaceuticals for diagnosing Alzheimer's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Radiopharmaceuticals for diagnosing Alzheimer's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radiopharmaceuticals for diagnosing Alzheimer's disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3255212